References
- Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004;122:336–40
- Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462–8
- Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425–7
- Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247–8
- Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone acetonide for diffuse macular edema. Arch Ophthalmol 2003;121:57–61
- Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920–7
- Antoszyk AN, Gottlieb JL, Machemer R, et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34–40
- Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age related macular degeneration. Arch Ophthalmol 2003;121:667–73
- Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and triamcinolone: a pilot study. Aust N Z J Ophthalmol 1995;23:293–8
- Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina 1996;16:166–7
- McCluskey P, Forrester J, Lightman S. Uniocular macular oedema and reduced vision in a patient with uveitis. Clin Experiment Ophthalmol 2000;28:9–12
- Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431–2
- Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2–6
- Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380–3
- Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246–9
- Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol 1966;76:477–83
- Becker B, Ballin N. Glaucoma and corticosteroid provocative testing. Arch Ophthalmol 1965;74:621–4
- Bigger JF, Palmberg PF, Zink H, et al. Sensitivity to glucocorticoids in primary open angle glaucoma. N Engl J Med 1972;287:992
- Bartlett JD, Woodley TW, Adams CM. Identification of high IOP responders to topical ophthalmic corticosteroids. J Ocular Pharmacol 1993;9:35–45
- Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386–90
- Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24–7
- Beer PM, Sophie JB, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681–6
- Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci 2003;44:473–85